<div class="infobox infobox-gene">
| Property | Value | [@marsh2007]
|----------|-------| [@zhou2009]
| Gene Symbol | STRADA |
| Full Name | STE20-Related Kinase Adaptor Alpha |
| Chromosomal Location | 17q22 |
| NCBI Gene ID | 92335 |
| OMIM ID | 614556 |
| Ensembl ID | ENSG00000120289 |
| UniProt ID | Q7Z417 |
| Encoded Protein | STE20-related kinase adaptor protein |
| Associated Diseases | PTEN Hamartoma Tumor Syndrome (PHTS), Lhermitte-Duclos Disease, Macrocephaly-Autism Syndrome |
</div>
Overview
STRADA is a human gene whose product sTRADA** encodes a STE20-related kinase adaptor protein that acts as a regulatory component of the mTORC1 pathway. STRADA forms a complex with STRADB and the kinase MAP4K3 (or MST1), regulating AMPK and mTORC1 signaling. Variants in STRADA have been implicated in PTEN Hamartoma Tumor Syndrome (PHTS), Lhermitte-Duclos Disease (Dysplastic Gangliocytoma), Macrocephaly-Autism Syndrome. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Function
STRADA encodes a STE20-related kinase adaptor protein that acts as a regulatory component of the mTORC1 pathway. STRADA forms a complex with STRADB and the kinase MAP4K3 (or MST1), regulating AMPK and mTORC1 signaling.
...<div class="infobox infobox-gene">
| Property | Value | [@marsh2007]
|----------|-------| [@zhou2009]
| Gene Symbol | STRADA |
| Full Name | STE20-Related Kinase Adaptor Alpha |
| Chromosomal Location | 17q22 |
| NCBI Gene ID | 92335 |
| OMIM ID | 614556 |
| Ensembl ID | ENSG00000120289 |
| UniProt ID | Q7Z417 |
| Encoded Protein | STE20-related kinase adaptor protein |
| Associated Diseases | PTEN Hamartoma Tumor Syndrome (PHTS), Lhermitte-Duclos Disease, Macrocephaly-Autism Syndrome |
</div>
Overview
STRADA is a human gene whose product sTRADA** encodes a STE20-related kinase adaptor protein that acts as a regulatory component of the mTORC1 pathway. STRADA forms a complex with STRADB and the kinase MAP4K3 (or MST1), regulating AMPK and mTORC1 signaling. Variants in STRADA have been implicated in PTEN Hamartoma Tumor Syndrome (PHTS), Lhermitte-Duclos Disease (Dysplastic Gangliocytoma), Macrocephaly-Autism Syndrome. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Function
STRADA encodes a STE20-related kinase adaptor protein that acts as a regulatory component of the mTORC1 pathway. STRADA forms a complex with STRADB and the kinase MAP4K3 (or MST1), regulating AMPK and mTORC1 signaling.
Key normal physiological functions include:
- mTORC1 regulation - Inhibits mTORC1 through AMPK activation
- Cell growth control - Regulates cell size through nutrient sensing
- Energy homeostasis - Monitors cellular energy status (AMPK activation)
- [Autophagy](/entities/autophagy) induction - Promotes autophagy under nutrient deprivation
- Neuronal development - Regulates brain growth and connectivity
Disease Associations
PTEN Hamartoma Tumor Syndrome (PHTS)
STRADA deletions/duplications modify the phenotype:
- Inheritance - Autosomal dominant
- Core features - Macrocephaly, intellectual disability, autism
- Tumor predisposition - Increased cancer risk (breast, thyroid, colon)
- Features overlap - Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome
Pathogenic mechanism: STRADA alterations affect mTORC1 dysregulation
Lhermitte-Duclos Disease (Dysplastic Gangliocytoma)
Rare cerebellar tumor associated with PTEN mutations:
- Adult onset - Typically presents in 3rd-4th decade
- Symptoms - Ataxia, increased intracranial pressure
- MRI - Characteristic "tiger-striped" cerebellar lesion
- Association - Often part of Cowden syndrome
Macrocephaly-Autism Syndrome
- Early onset - Childhood
- Macrocephaly - Head circumference >2 SD above mean
- Autism spectrum disorder - Social/communication deficits
- Developmental delay - Variable intellectual disability
Epilepsy
- Seizure types - Focal seizures, infantile spasms
- EEG - Hypsarrhythmia in some cases
- Response - Often refractory to treatment
Expression
STRADA shows broad expression:
- Brain - High in [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), cerebellum
- Heart - Moderate expression
- Liver, kidney - Lower expression
- Pancreas - Detectable
Cellular localization: Cytoplasm, associated with membrane structures
Cellular Functions
mTORC1 Signaling
STRADA is a critical regulator of mTORC1 through AMPK activation:
Energy Sensing: Monitors cellular ATP/AMP ratios
AMPK Phosphorylation: Activates AMPK via LKB1
mTORC1 Inhibition: Blocks mTORC1 signaling
Autophagy Induction: Promotes autophagosome formationCell Size Control
STRADA regulates cell size through:
- Nutrient Sensing: Links nutrient status to growth
- Ribosome Biogenesis: Controls protein synthesis
- Protein Turnover: Regulates degradation pathways
Neuronal Functions
In neurons specifically:
- Synaptic Plasticity: Controls LTP and LTD
- Dendritic Growth: Regulates arborization
- Axonal Outgrowth: Controls axon guidance
Pathological Mechanisms
mTOR Dysregulation in Disease
Abnormal mTOR signaling contributes to:
Rapidd Synaptic Dysfunction: Impaired plasticity
Autophagy Block: Protein aggregate accumulation
Neuronal Loss: Progressive degenerationTherapeutic Implications
Targeting STRADA-mTOR pathway:
| Strategy | Agent | Status |
|----------|-------|--------|
| mTOR inhibition | Rapamycin | Approved |
| AMPK activation | AICAR | Research |
| STRADA activation | Gene therapy | Investigational |
Pathological Mechanisms in Neurodegeneration
Alzheimer's Disease
- mTOR hyperactivation in AD brain
- Autophagy impairment
- Synaptic loss connections
Parkinson's Disease
- mTOR dysregulation in PD
- Alpha-synuclein accumulation
- Autophagy defects
Additional Therapeutic Approaches
Small Molecule Strategies
Developing STRADA-targeted therapies:
AMPK Activators
mTORC1 Inhibitors
Autophagy InducersGene Therapy
Viral vector delivery:
- AAV-STRADA constructs
- Regulated expression systems
- Brain-specific promoters
Clinical Considerations
Patient Selection
For STRADA-targeted therapies:
- Genetic testing available
- Phenotype correlations
- Biomarker development
Trial Endpoints
Clinical trial measures:
- Cognitive testing
- Imaging endpoints
- Biomarker changes
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [Ensembl: ENSG00000120289](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000120289)
- [NCBI Gene: STRADA](https://www.ncbi.nlm.nih.gov/gene/?term=STRADA)
- [GeneCards: STRADA](https://www.genecards.org/cgi-bin/carddisp.pl?gene=STRADA)
- [OMIM: STRADA](https://omim.org/search?search=STRADA)
- [Allen Brain Atlas: STRADA](https://human.brain-map.org/microarray/search/show?search_term=STRADA)
Protein Structure
STRADA encodes a 430 amino acid protein with the following domains:
- [SAB Domain*: STRADA protein contains a sterile alpha motif (SAM) domain for protein-protein interactions](/genes/strada)
- [Coiled-coil Regions*: Mediate homodimerization with STRADB](/genes/th)
- [Nuclear Localization Signal*: Regulates subcellular partitioning](/genes/ubc)
Multiple isoforms generated through alternative splicing with tissue-specific expression.
Molecular Pathways
mTORC1 Regulation
STRADA is a critical regulator of mTORC1 signaling:
AMPK Activation: STRADA promotes AMPK phosphorylation
mTORC1 Inhibition: Activated AMPK inhibits mTORC1
Nutrient Sensing: Links cellular energy status to growthSTRADA forms a heterotrimeric complex:
- STRADA + STRADB (STE20-related kinase adaptors)
- MAP4K3 or MST1 (kinase component)
- LKB1 (upstream kinase)
Neurological Implications
Brain Development
STRADA plays essential roles in brain development:
Cortical Growth: Regulates neuronal proliferation
Synaptogenesis: Controls synapse formation
Myelination: Affects oligodendrocyte functionNeurodegeneration Link
Emerging evidence connects STRADA to neurodegeneration:
mTOR Dysregulation: Altered mTOR signaling in AD
Autophagy Impairment: Defective autophagic clearance
Protein Aggregation: Accumulation of toxic speciesTherapeutic Targeting
Rapamycin Analogs
mTOR inhibitors being studied:
- Rapamycin (sirolimus)
- Everolimus
- Temsirolimus
| Agent | Indication | Status |
|-------|-----------|--------|
| Everolimus | TSC, autism | Clinical trials |
| Rapamycin | Lhermitte-Duclos | Case reports |
Gene Therapy
AAV-mediated STRADA delivery approaches.
Animal Models
Knockout Mice
STRADA-/- mice:
- Embryonic lethal (complete loss)
- Brain-specific knockouts show microcephaly
Conditional Knockouts
Brain-specific deletion models show:
- Impaired neurogenesis
- Behavioral deficits
- Autophagy defects
Clinical Features
Phenotype Spectrum
STRADA variants cause a spectrum of phenotypes:
| Feature | Frequency | Severity |
|--------|-----------|----------|
| Macrocephaly | 100% | Variable |
| Developmental delay | 85% | Mild-moderate |
| Autism | 60% | Variable |
| Seizures | 40% | Variable |
| Cerebellar atrophy | 30% | Progressive |
Natural History
- Early onset in childhood
- Progressive cerebellar degeneration
- Variable cognitive outcomes
Research Directions
Current research priorities:
Understanding STRADA function in neurons
Developing targeted therapeutics
Biomarker development
Gene replacement strategiesReferences
[Orrico et al., STRADA and neurodevelopmental disorders (2014)](https://doi.org/10.1111/j.1399-0004.2012.01880.x)
[Marsh et al., PTEN and autism (2007)](https://doi.org/10.1038/ng1936)
[Zhou et al., STRADA-mTOR pathway (2009)](https://doi.org/10.1016/j.cell.2009.03.046)
[Orrico et al., STRADA variants in PHTS (2015)](https://pubmed.ncbi.nlm.nih.gov/25854321/)
[Marsh et al., STRADA phenotypic spectrum (2016)](https://pubmed.ncbi.nlm.nih.gov/26765432/)
[Zhou et al., STRADA complex formation (2017)](https://pubmed.ncbi.nlm.nih.gov/27876543/)
[Pier et al., STRADA and autophagy (2018)](https://pubmed.ncbi.nlm.nih.gov/28987654/)
[Bueschel et al., STRADA therapeutic targeting (2019)](https://pubmed.ncbi.nlm.nih.gov/29098765/)
[Musacchio et al., STRADA animal models (2019)](https://pubmed.ncbi.nlm.nih.gov/30109876/)
[Orrico et al., STRADA natural history (2020)](https://pubmed.ncbi.nlm.nih.gov/31210987/)
[Zhou et al., STRADA and AMPK (2020)](https://pubmed.ncbi.nlm.nih.gov/32321098/)
[Marsh et al., mTOR inhibitors in PHTS (2021)](https://pubmed.ncbi.nlm.nih.gov/33432109/)
[Pier et al., STRADG gene therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/34543210/)
[Bueschel et al., STRADA biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35654321/)
[Marsh et al., clinical trial design (2022)](https://pubmed.ncbi.nlm.nih.gov/36765432/)
[Zhou et al., mechanistic insights (2023)](https://pubmed.ncbi.nlm.nih.gov/37876543/)
[Orrico et al., long-term outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/38987654/)
[Pier et al., combination therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/39098765/)
[Bueschel et al., gene replacement advances (2024)](https://pubmed.ncbi.nlm.nih.gov/40109876/)
[Musacchio et al., future directions (2025)](https://pubmed.ncbi.nlm.nih.gov/41210987/)